#40 Avacopan in ANCA-Associated Vasculitis, with Lorraine Harper

Steroids have long been a cornerstone in treating ANCA-associated vasculitis, but their toxicity remains a significant challenge. Could Avacopan, a selective oral C5a receptor antagonist, provide a safer and more effective alternative? In this episode, you’ll hear about what’s new in the pathophysiology of ANCA vasculitis, current remission induction therapies, the place of Avacopan in the treatment protocols and future possibilities for managing this complex condition. Guiding us through these topics is Lorraine Harper, a distinguished specialist from the University of Birmingham, whose expertise in immunology and vasculitis offers invaluable insights into the latest advancements.